Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting

François Montastruc, Haleh Bagheri, Isabelle Lacroix, Christine Damase-Michel, Leila Chebane, Vanessa Rousseau, Emilie Jouanjus, Maryse Lapeyre-Mestre, Geneviève Durrieu and Jean-Louis Montastruc ()
Additional contact information
François Montastruc: Centre Hospitalier Universitaire de Toulouse
Haleh Bagheri: Centre Hospitalier Universitaire de Toulouse
Isabelle Lacroix: Centre Hospitalier Universitaire de Toulouse
Christine Damase-Michel: Centre Hospitalier Universitaire de Toulouse
Leila Chebane: Centre Hospitalier Universitaire de Toulouse
Vanessa Rousseau: Centre Hospitalier Universitaire de Toulouse
Emilie Jouanjus: Centre Hospitalier Universitaire de Toulouse
Maryse Lapeyre-Mestre: Centre Hospitalier Universitaire de Toulouse
Geneviève Durrieu: Centre Hospitalier Universitaire de Toulouse
Jean-Louis Montastruc: Centre Hospitalier Universitaire de Toulouse

Drug Safety, 2018, vol. 41, issue 5, No 6, 514 pages

Abstract: Abstract Introduction The use of mobile apps is increasing in medicine. In pharmacovigilance, mobile apps may help to increase adverse drug reaction reporting and improve the communication of safety issues. The Toulouse University Pharmacovigilance Center has developed VigiBIP®, a free smartphone app available on Android and Apple stores, for reporting adverse drug reactions and requesting drug safety information. Objective The present study was performed to compare the main characteristics of spontaneous adverse drug reaction reports received through VigiBIP® with classical methods of reporting (phone, e-mail, fax, letter, website) during 25 months (2015–17). Methods Using the Chi squared test, we compared the type of reporter, adverse drug reaction seriousness, drugs involved and reported ADRs using VigiBIP® and classical methods of reporting Results A total of 4102 reports were received by the Toulouse University Pharmacovigilance Center, including 4.7% through VigiBip®. Patients’ reports were significantly more frequent with VigiBip® (6.7%) than with classical methods (3.4%) [p = 0.01]. Reported adverse drug reactions and involved drugs differed according to the method of reporting used. Conclusion Our study shows that a mobile app is an additional tool used in pharmacovigilance. Types of reporters and adverse drug reactions in VigiBIP were different to those seen in classical methods of reporting.

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-017-0630-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:41:y:2018:i:5:d:10.1007_s40264-017-0630-2

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-017-0630-2

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().